Search

Your search keyword '"Doranz, Benjamin J."' showing total 8 results
Start Over Author "Doranz, Benjamin J." Journal mabs
8 results on '"Doranz, Benjamin J."'

2. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries

Author

Yuan, Tom Z., primary, Garg, Pankaj, additional, Wang, Linya, additional, Willis, Jordan R., additional, Kwan, Eric, additional, Hernandez, Ana G Lujan, additional, Tuscano, Emily, additional, Sever, Emily N., additional, Keane, Erica, additional, Soto, Cinque, additional, Mucker, Eric M., additional, Fouch, Mallorie E., additional, Davidson, Edgar, additional, Doranz, Benjamin J., additional, Kailasan, Shweta, additional, Aman, M. Javad, additional, Li, Haoyang, additional, Hooper, Jay W., additional, Saphire, Erica Ollmann, additional, Crowe, James E., additional, Liu, Qiang, additional, Axelrod, Fumiko, additional, and Sato, Aaron K., additional

Published
2021
Full Text
View/download PDF

6. Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures

Author

Cox, Kara S., primary, Tang, Aimin, additional, Chen, Zhifeng, additional, Horton, Melanie S., additional, Yan, Hao, additional, Wang, Xin-Min, additional, Dubey, Sheri A., additional, DiStefano, Daniel J., additional, Ettenger, Andrew, additional, Fong, Rachel H., additional, Doranz, Benjamin J., additional, Casimiro, Danilo R., additional, and Vora, Kalpit A., additional

Published
2015
Full Text
View/download PDF

8. The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics.

Author

Norden DM, Navia CT, Sullivan JT, and Doranz BJ

Subjects
Humans, Antibody Specificity, Animals, Protein Binding, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal immunology, Protein Array Analysis methods
Abstract

Specificity profiling is a requirement for monoclonal antibodies (mAbs) and antibody-directed biotherapeutics such as CAR-T cells prior to initiating human trials. However, traditional approaches to assess the specificity of mAbs, primarily tissue cross-reactivity studies, have been unreliable, leading to off-target binding going undetected. Here, we review the emergence of cell-based protein arrays as an alternative and improved assessment of mAb specificity. Cell-based protein arrays assess binding across the full human membrane proteome, ~6,000 membrane proteins each individually expressed in their native structural configuration within live or unfixed cells. Our own profiling indicates a surprisingly high off-target rate across the industry, with 33% of lead candidates displaying off-target binding. Moreover, about 20% of therapeutic mAbs in clinical development and currently on the market display off-target binding. Case studies and off-target rates at different phases of biotherapeutic drug approval suggest that off-target binding is likely a major cause of adverse events and drug attrition.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results